Shenzhen Lifotronic Technology (688389) Fundamentals 2026 — P/E 28.2x, Revenue Analysis | SniperIQ
Shenzhen Lifotronic Technology (688389) is a CN-listed Healthcare company in Medical - Specialties with a market capitalization of ¥4.6B, trading at ¥10.74 on the SHH. This SniperIQ fundamentals page covers Shenzhen Lifotronic Technology's valuation (P/E 28.2x, P/B 2.0x), profitability (net margin 15.2%), revenue (¥1.0B in FY2025), balance-sheet quality, and AI signal context — from live market data, research only.
Full research coverage
- 8-Quarter Revenue & Margin Trend
- Debt Maturity & Coverage
- Peer Valuation Comparison
- Free Cash Flow & Owner Earnings
- AI Signal + Institutional Flow
- DCF Valuation Model
Frequently Asked Questions
What is Shenzhen Lifotronic Technology's market cap?
Shenzhen Lifotronic Technology (688389) has a market capitalization of approximately ¥4.6B, trading at ¥10.74 on the SHH. Market cap moves with the live share price.
What is Shenzhen Lifotronic Technology's P/E ratio?
Shenzhen Lifotronic Technology's trailing twelve-month P/E ratio is 28.2x, with a price-to-book (P/B) of 2.0x. Valuation multiples are best compared with Healthcare sector peers rather than read in isolation.
How profitable is Shenzhen Lifotronic Technology?
Shenzhen Lifotronic Technology runs a net profit margin of 15.2%, a gross margin of 97.6%, and an operating margin of 15.0%. Margins and ROE indicate how efficiently the business converts sales into profit and shareholder returns.
How much revenue does Shenzhen Lifotronic Technology generate?
Shenzhen Lifotronic Technology reported revenue of ¥1.0B for fiscal year 2025, with net income of ¥186M and earnings per share (EPS) of 0.43. SniperIQ tracks the full 8-quarter revenue and margin trend on the research dashboard.
Does Shenzhen Lifotronic Technology pay a dividend?
Shenzhen Lifotronic Technology offers a trailing dividend yield of about 2.6%. Dividend sustainability depends on payout ratio, free cash flow, and earnings stability — all tracked in SniperIQ's fundamentals view.
Is Shenzhen Lifotronic Technology financially healthy?
Shenzhen Lifotronic Technology carries a debt-to-equity ratio of 0.07x and a current ratio of 4.34x, with a market beta of 0.44. Lower leverage and a current ratio above 1.0 generally signal a stronger balance sheet.
Is Shenzhen Lifotronic Technology a good stock to buy in 2026?
SniperIQ provides research-only market intelligence, not personalised financial advice or a buy/sell call. For Shenzhen Lifotronic Technology (688389) the key facts are: market cap ¥4.6B, P/E 28.2x, revenue ¥1.0B, 52-week range 9.36-14.88. Weigh valuation, profitability, growth, and balance-sheet strength against Healthcare peers and form your own view.
Track Shenzhen Lifotronic Technology's full fundamentals live
Get Shenzhen Lifotronic Technology's 8-quarter revenue and margin trend, peer comparison, DCF model, and AI signal on the SniperIQ research dashboard.